Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States

BMC Neurology

卷:23

Research

Divya Asher¹  Meghana Karnik-Henry¹  Steven Kymes¹  Seema Soni-Brahmbhatt¹  Amaal J. Starling² 

[1] Lundbeck LLC, Deerfield, IL, USA;

[2] Mayo Clinic Arizona, 13400 East Shea Boulevard, 85259, Scottsdale, AZ, USA;

关键词: Eptinezumab;    Headache;    Migraine;    Monoclonal antibody;    Preventive treatment;   

DOI  :  10.1186/s12883-023-03204-8

 received in 2022-08-12, accepted in 2023-04-11,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe efficacy and safety of eptinezumab for preventive migraine treatment in adults have been demonstrated in multiple, large-scale clinical trials. This non-interventional, retrospective, observational chart review was conducted to examine patient response to eptinezumab 100 mg or 300 mg every 12 weeks for 6 months in the clinical setting.MethodsEight headache specialists who reported early clinical experience with eptinezumab enrolled the first adults (1–6 adults per clinician; age ≥ 18 years) who met predefined selection criteria (including ≥ 12-month history of migraine, ≥ 4 migraine days/month prior to eptinezumab initiation, receipt of ≥ 2 consecutive eptinezumab doses, and ≥ 12-week follow-up period), and provided detailed patient, disease, treatment, and outcome information via SurveyMonkey and standardized case-report forms.ResultsCharts from 31 adults (median age, 49 years) with migraine (93.6% chronic) who received eptinezumab for the preventive treatment of migraine were reviewed. Most patients (26/31 [83.9%]) were initiated at 100 mg. Eptinezumab reduced mean headache frequency (24.3 monthly headache days [MHDs] at baseline; 17.1 MHDs at Month 6); mean migraine frequency (17.3 monthly migraine days [MMDs] at baseline; 9.1 MMDs at Month 6); attack severity (17/31 [54.8%] patients); acute headache medication use (12.5 acute medication days at baseline; 7.4 at Month 6); and patient-reported disability (11/22 [50.0%] severe at baseline; 7/19 [36.8%] at Month 6). More than three-quarters of patients (24/31 [77.4%]) perceived improved disability/function and most (30/31 [96.8%]) perceived eptinezumab to be well tolerated after 6 months. Most of the headache specialists reported that eptinezumab was well tolerated by patients (30/31 [96.8%]) and that the intravenous infusion experience was not challenging.ConclusionsPatients with migraine who received 6 months of preventive treatment with eptinezumab experienced reductions in migraine and headache frequency, disability, and acute medication use during the course of treatment.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 3

40507_2023_167_Article_IEq164.gif

Fig. 1